KUALA LUMPUR, 18 SEPTEMBER
2020 – Ho Wah Genting Berhad (“HWGB” or the
“Company”) (Bursa Stock Code:9601) today announced its wholly owned subsidiary HWGB Biotech Sdn Bhd’s
(“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture
partner, US-based E-MO Biology Inc. (“EBI”), had entered into three agreements for
R&D together with supporting investigative procedures leading to a COVID-19
vaccine, as follows:
Biology Inc (EBI) contracted Dr. John Andrews through Black Diamond Networks
(Professional service agreement) to support US FDA IND application project
based upon his 25 years direct experiences in regard to vaccine development
& clinical phase IV study.
Biology Inc (EBI) to engaged the
services of Roderick A. Comunale II MD Inc to conduct a clinical research study
entitled “Inactivated Polio Vaccine in prevention of COVID-19 in high risk
population in a Phase IV study", which shall study the effects of
Inactivate Polio Vaccine-IPV which shall be conducted according to the United
States Food and Drug Administration approved protocol and to be provided by
Biology Inc (EBI) collaboration with America Diagnostic & Genescan
E-MO Biology Inc (EBI) engage
the biomedical assay development services of America Diagnostic & Genescan
Diagnostics Inc to conduct a series of immunology assays in supporting the
potential clinic research entitled "Inactivated Polio Vaccine in
prevention of COVID-19 in Patients with general population in a Phase IV
Research and Development."
E-MO Biology Inc (EBI) to
collaborate with America Diagnostic & Genescan Diagnostics Inc as a
strategic partner involved with research, development and production of the
companion diagnostics systems.
Chief Executive Officer of
HWGB, Dato’ Aaron Lim said:
“The agreements facilitating the R&D including the clinical trials for a COVID-19
vaccine are crucial to the clinical trials. These agreements bring in the
needed expertise that will help boost the clinical trials that must be
conducted in accordance with US laws”.
“We look forward to the fruitful work that will come
from the collaborations with our partners and we again want to emphasise that
time is important in the production of the vaccine given how the pandemic has
ravaged through Southeast Asia’s population and weigh on its economy,” Dato
Aaron Lim added.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is
principally engaged in investment holdings and the provision of management
services to its subsidiaries. The Company had on 30 June 2020 diversified its
existing businesses to include healthcare related industry which mainly
involved in Health Supplement, Biotechnology and Health Technology. In
addition, the Company and its subsidiaries (“HWGB Group” or the “Group”)
are also engaging in the businesses of Investment holdings; manufacturing of
wire and cable and moulded power supply cord sets and cable assemblies for
electrical and electronic devices and equipment; trading of wire and cable; and
travel agent and tour related services.
Emo-Biology Inc (“EBI”) was
incorporated in the state of California in the United States of America on 24
May 2020. It is principally involved in conducting biology research and
development activities and is the sponsor of a study which indicates booster
polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Xie QiYi, who serves as its Managing Director of EBI.
He has over 30 years of experiences in areas of public health and infection
disease control. He was also involved in the development of medical and
diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for